Dual-Attack drug tested to shrink tumors before lung cancer surgery
NCT ID NCT07452003
Summary
This study is testing whether adding a new immunotherapy drug called QL1706 to standard chemotherapy improves outcomes for people with non-small cell lung cancer who are scheduled for surgery. About 30 participants will receive the drug combination before their operation, aiming to shrink the tumor, and will be monitored after surgery to see if the cancer returns. The main goal is to see if very little cancer is left in the tumor after this pre-surgery treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.